NCT02919800View on ClinicalTrials.gov

A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 22, 2017

Primary Completion Date

February 21, 2018

Study Completion Date

February 21, 2018

Conditions
Hemophilia A or B With Inhibitors
Interventions
BIOLOGICAL

MOD-5014

MOD-5014, a long-acting modified recombinant Factor VIIa

OTHER

MOD-5014 Placebo

Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes

Trial Locations (1)

Unknown

TASMC, Tel Aviv

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT02919800 - A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male | Biotech Hunter | Biotech Hunter